Welcome to our dedicated page for Cb Scientific news (Ticker: CBSC), a resource for investors and traders seeking the latest updates and insights on Cb Scientific stock.
CB Scientific Inc (CBSC) delivers innovative non-invasive cardiac monitoring solutions through advanced EKG devices and integrated cloud-based software. This news hub provides investors and healthcare professionals with timely updates on company developments, regulatory milestones, and technological advancements in remote patient care.
Access a centralized repository of press releases and financial announcements to track CB Scientific's progress in enhancing cardiac diagnostics. The page consolidates essential information including product launches, partnership agreements, and clinical validation studies, offering stakeholders a comprehensive view of the company's market position.
Key updates cover advancements in ambulatory monitoring systems, global distribution expansions, and software innovations that improve data accuracy for clinicians. Regular updates ensure visitors stay informed about CBSC's contributions to digital health and medical device technology.
Bookmark this page for direct access to verified CB Scientific news. Check back frequently for objective reporting on operational developments and strategic initiatives shaping the future of cardiac care technology.
CB Scientific Inc. (CBSC) has officially launched its next generation MyCardia AT cardiac monitor in partnership with contract manufacturer Datrix, This FDA-cleared device is designed for the company's international distribution network in SE Asia, Hong Kong, and Macau.
The MyCardia AT offers an improved patient monitoring experience with its lightweight, easy-to-wear design and flexible options to transmit event recordings via iOS or Android smartphones using the MyCardia app. The device helps physicians detect cardiac arrhythmias in patients with intermittent symptoms during a 30-day monitoring period, addressing a critical health concern as ischemic heart disease deaths have increased from 2.7 million to 9.1 million since 2000.
CBSC is strategically enhancing its cardiac monitoring portfolio by integrating the device with its existing AWS Cloud-based MyCardia portal and smartphone applications. Distributors in Malaysia, Singapore, Thailand, Indonesia, Hong Kong, and Macau will begin registering the device with regulatory agencies, with plans to expand to China and Canada pending regulatory approvals.
CB Scientific (OTC PINK:CBSC), a company specializing in non-invasive ambulatory cardiac monitoring products and services, has appointed William "Trip" Thomas as its new Chief Financial Officer, effective October 1, 2024. This appointment follows the resignation of Brooke Turk, who stepped down on September 30, 2024. The company clarified that Turk's departure was not due to any disagreement or conflict.
Mr. Thomas brings a strong educational background to his new role, holding a Bachelor of Science in Accounting from the University of Tampa and a Bachelor of Science in Agribusiness from the University of Florida. Additionally, he is a licensed Certified Public Accountant in the State of Florida, further solidifying his qualifications for the position.
CB Scientific (OTC PINK:CBSC), a company focused on non-invasive ambulatory cardiac monitoring products, has announced its voluntary delisting from the OTCQB Venture Market. This decision aims to preserve capital for implementing the company's business plan. Importantly, CBSC's common stock will continue trading on the OTC Pink Open Market, allowing shareholders to maintain their ability to trade shares in the public market. The company states that it plans to re-engage an auditor and apply for uplisting when certain milestones are achieved and conditions are appropriate.
CB Scientific (OTCQB: CBSC) has announced an exclusive 5-year distribution agreement with Your Heart Protector Corp. in Canada. This agreement will allow Your Heart Protector to market CBSC's non-invasive cardiac monitoring products and provide related services. The partnership includes developing cloud-based software and mobile applications, as well as facilitating regulatory approvals for the myCam 1.1 device. CBSC is also working on obtaining FDA clearance for myCam 1.1 to expand its market reach. The company is committed to keeping investors updated on future developments.
CB Scientific (OTCQB:CBSC) has completed regulatory testing for its enhanced myCam cardiac event monitor and submitted a 510(k) application to the FDA for market clearance. The updated design offers reduced power consumption, improved signal quality, and superior materials that cut component lead times by over 50%. The company expects FDA feedback within 90 to 120 days. Following clearance, CBSC aims to market the device in the U.S. and internationally, including Asia and Latin America, enhancing its competitive position in the cardiac monitoring market.
CB Scientific, Inc. (CBSC) has announced a manufacturing partnership with Shenzhen Pump Medical Co., Ltd. to produce its myCam cardiac monitoring device and related software in China. This agreement recognizes Shenzhen Pump as the official manufacturer, compliant with local regulatory standards. CBSC's myCam has demonstrated high performance with over 2.1 million patient interactions and a 99+% efficiency rate in trials. The collaboration aims to expedite the regulatory approval process by the National Medical Products Administration (NMPA).
CB Scientific, Inc. (OTCQB:CBSC) has announced it has entered the regulatory testing phase for its enhanced myCam cardiac event monitoring device, aiming for FDA 510(k) clearance. The new myCam features improved power consumption, lead wire shielding, signal quality, and cost-effective sourcing, maintaining core functionalities while enhancing market competitiveness. Expected submission for FDA approval is imminent, with product delivery plans for Asia, Latin America, and the Middle East upon clearance.
CB Scientific has appointed James Ott as the new Chief Technology Officer, effective immediately. With over 28 years of experience in ambulatory ECG and clinical research, Ott aims to drive technological innovation and business expansion. His extensive background includes leadership roles in product development, regulatory compliance, and significant contributions to U.S. patent submissions. The company, which specializes in non-invasive cardiac monitoring products, expresses confidence in Ott's ability to enhance investor value and improve healthcare solutions.
FAQ
What is the current stock price of Cb Scientific (CBSC)?
What is the market cap of Cb Scientific (CBSC)?
